TRAVOPROST OPHTHALMIC SOLUTION 0.004%- travoprost solution United States - English - NLM (National Library of Medicine)

travoprost ophthalmic solution 0.004%- travoprost solution

par pharmaceutical, inc. - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travoprost 0.04 mg in 1 ml - travoprost ophthalmic solution usp, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. none pregnancy category c teratogenic effects: travoprost was teratogenic in rats, at an intravenous (iv) dose up to 10 mcg/kg/day (250 times the maximal recommended human ocular dose (mrhod), evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, such as fused sternebrae, domed head and hydrocephaly. travoprost was not teratogenic in rats at iv doses up to 3 mcg/kg/day (75 times the mrhod), or in mice at subcutaneous doses up to 1 mcg/kg/day (25 times the mrhod). travoprost produced an increase in post-implantation losses and a decrease in fetal viability in rats at iv doses >3 mcg/kg/day (75 times the mrhod) and in mice at subcutaneous doses >0.3 mcg/kg/day (7.5 times the mrhod). in the offspring of female rats that received travoprost subcutaneously from day 7 of pregnancy to lacta

Travoprost 40mcg/ml eye drops solution Malta - English - Medicines Authority

travoprost 40mcg/ml eye drops solution

1 a pharma gmbh keltenring 1+3, 82041 oberhaching, germany - travoprost - eye drops, solution - travoprost 40 µg - ophthalmologicals

Travoprost Bipharma 40 µg/ml eye drops sol. dropper cont. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

travoprost bipharma 40 µg/ml eye drops sol. dropper cont.

bipharma b.v. - travoprost 0,04 mg/ml - eye drops, solution - 40 µg/ml - travoprost 0.04 mg/ml - travoprost

Travoprost EG 40 µg/ml eye drops sol. dropper cont. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

travoprost eg 40 µg/ml eye drops sol. dropper cont.

eg sa-nv - travoprost 0,04 mg/ml - eye drops, solution - 40 µg/ml - travoprost 0.04 mg/ml - travoprost

Travoprost Sandoz 40 µg/ml eye drops sol. dropper cont. Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

travoprost sandoz 40 µg/ml eye drops sol. dropper cont.

sandoz sa-nv - travoprost 0,004 % v/v - 100 % v/v - eye drops, solution - 40 µg/ml - travoprost 0.04 mg/ml - travoprost

TRAVOPROST S.K. Israel - English - Ministry of Health

travoprost s.k.

k.s.kim international (sk- pharma) ltd., israel - travoprost - ophthalmic solution - travoprost 0.04 mg/ml - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication

TRAVOPROST OPHTHALMIC SOLUTION USP, 0.004% TRAVOPROST- travoprost ophthalmic solution usp, 0.004% solution/ drops United States - English - NLM (National Library of Medicine)

travoprost ophthalmic solution usp, 0.004% travoprost- travoprost ophthalmic solution usp, 0.004% solution/ drops

alembic pharmaceuticals inc. - travoprost (unii: wj68r08kx9) (travoprost - unii:wj68r08kx9) - travoprost ophthalmic solution usp, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. none pregnancy category c teratogenic effects: travoprost was teratogenic in rats, at an intravenous (iv) dose up to 10 mcg/kg/day (250 times the maximal recommended human ocular dose (mrhod), evidenced by an increase in the incidence of skeletal malformations as well as external and visceral malformations, such as fused sternebrae, domed head and hydrocephaly. travoprost was not teratogenic in rats at iv doses up to 3 mcg/kg/day (75 times the mrhod), or in mice at subcutaneous doses up to 1 mcg/kg/day (25 times the mrhod). travoprost produced an increase in post-implantation losses and a decrease in fetal viability in rats at iv doses >3 mcg/kg/day (75 times the mrhod) and in mice at subcutaneous doses >0.3 mcg/kg/day (7.5 times the mrhod). in the offspring of female rats that received travoprost subcutaneously from day 7 of pregnanc

DP-Travoprost New Zealand - English - Medsafe (Medicines Safety Authority)

dp-travoprost

douglas pharmaceuticals limited - travoprost 40 µg/ml - eye drops, solution - 40 mcg/ml - active: travoprost 40 µg/ml excipient: benzalkonium chloride boric acid disodium edetate 1 m sodium hydroxide/1 m hydrochloric acid (ph 5.8-6.2) mannitol polyethylene glycol hydrogenated castor oil purified water trometamol - dp-travoprost eye drops are indicated to decrease elevated intraocular pressure in ocular hypertension and open-angle glaucoma as monotherapy or as adjunctive therapy.

TRAVATAN Israel - English - Ministry of Health

travatan

novartis israel ltd - travoprost - ophthalmic solution - travoprost 0.004 %w/v - travoprost - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication.

TRAVATAN 0.004% travoprost 40 microgram/mL eye drop solution bottle Australia - English - Department of Health (Therapeutic Goods Administration)

travatan 0.004% travoprost 40 microgram/ml eye drop solution bottle

novartis pharmaceuticals australia pty ltd - travoprost, quantity: 40 microgram/ml - eye drops, solution - excipient ingredients: boric acid; ethoxylated hydrogenated castor oil; polyquaternium-1; sodium hydroxide; mannitol; hydrochloric acid; propylene glycol; purified water; sodium chloride - travatan eye drops are indicated to decrease elevated intraocular pressure in: - ocular hypertension. - open-angle glaucoma. travatan eye drops may be used: - as first line monotherapy. - as adjunctive therapy.